

**Supplementary table 1. Phase III clinical trials comparing R-CHOP vs R-CHOP plus a targeted drug.**

<b>Clinical trials. Identifier</b>	<b>Clinical trial.</b>	<b>Status</b>
NCT03777085	A Study to Compare the Efficacy and Safety of JHL 1101 Versus Rituximab in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)	Completed, no results
NCT01659099	GA In Newly Diagnosed Diffuse Large B Cell Lymphoma (GAINED)	Completed, no results
NCT04231448	Phase III Study of Tocidinostat in Combination with R-CHOP in Patients with Newly Diagnosed Double-Expressor DLBCL.	Recruiting
NCT03263026	Study to Assess Enzastaurin + RCHOP in Subjects with DLBCL With the Genomic Biomarker DGM1™	Recruiting
NCT03274492	A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Participants with Diffuse Large B-Cell Lymphoma (POLARIX).	Recruiting
NCT02871869	Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma.	Recruiting
NCT03984448	Testing the Addition of a New Anti-cancer Drug, Venetoclax to Usual Chemotherapy for High Grade B-Cell Lymphomas.	Recruiting
NCT04529772	A Combination of Acalabrutinib with R-CHOP in Subjects With Previously Untreated Non-GCB Subtype DLBCL (ACE-LY-312).	Not yet recruiting